NEW YORK (TheStreet) -- Shares of Allergan (AGN) - Get Report closed up by 7.82% to $271.81 on heavy trading volume on Wednesday, after the company updated its second half outlook for fiscal 2015.

The drug company said that it expects second half revenues above $8 billion with earnings in the $6.25 per share to $6.65 per share range.

After its $40.5 billion merger with Teva Pharmaceutical (TEVA) - Get Report goes through, the company expects branded revenue to grow 10% with gross margins between 77% and 79%, Allergan said.

Allergan traded 6.57 million shares today, well ahead of the stock's three month daily trading average of 2.73 million shares.

Separately, TheStreet Ratings team rates ALLERGAN PLC as a Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation:

We rate ALLERGAN PLC (AGN) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • AGN's very impressive revenue growth greatly exceeded the industry average of 7.0%. Since the same quarter one year prior, revenues leaped by 115.8%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • Net operating cash flow has significantly increased by 157.87% to $1,401.30 million when compared to the same quarter last year. In addition, ALLERGAN PLC has also vastly surpassed the industry average cash flow growth rate of -10.43%.
  • The current debt-to-equity ratio, 0.59, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.78 is somewhat weak and could be cause for future problems.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 599.2% when compared to the same quarter one year ago, falling from $48.70 million to -$243.10 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, ALLERGAN PLC's return on equity significantly trails that of both the industry average and the S&P 500.
  • You can view the full analysis from the report here: AGN